{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:42Z","timestamp":1785387582138,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"\n Objective<\/jats:title>\n The objective of this study is to explore the prognostic value of serum total bilirubin for major adverse cardiovascular events (MACE), cardiovascular death (CV death), and all-cause mortality in coronary heart disease (CHD) patients after percutaneous coronary intervention (PCI).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Databases (PubMed, Cochrane Library, Embase, Web of Science) were searched up to May 2026). Studies were screened via PICOS. Two researchers independently extracted data and assessed study quality using Newcastle-Ottawa Scale. Meta-analysis was performed using STATA 16.0. Subgroup analysis was performed to explore the source of heterogeneity, and Egger's test was conducted to examine publication bias.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, 17 observational studies involving 27,580 patients with CHD undergoing PCI were included. Methodological quality was generally high (NOS score \u22657). The primary analyses were performed with\n a priori<\/jats:italic>\n stratification by follow-up setting. In the long-term follow-up subgroup (12 studies), although a high total bilirubin level was significantly associated with a lowered risk of MACEs (pooled OR\u2009=\u20090.65, 95% CI 0.46\u20130.92,\n P<\/jats:italic>\n \u2009=\u20090.016), substantial heterogeneity was observed within the subgroup (I\n 2<\/jats:sup>\n \u2009=\u200986.5%). A significant protective effect was also noted for all-cause mortality (7 studies; OR\u2009=\u20090.59, 95% CI 0.39\u20130.89,\n P<\/jats:italic>\n \u2009=\u20090.011), with moderate heterogeneity (I\n 2<\/jats:sup>\n \u2009=\u200953.6%). For CV death (9 studies), no statistical significance was reached (OR\u2009=\u20090.71, 95% CI 0.43\u20131.18,\n P<\/jats:italic>\n \u2009=\u20090.187). In the in-hospital acute-phase subgroup, high bilirubin was associated with a significantly increased risk of MACEs (5 studies; OR\u2009=\u20092.33, 95% CI 1.72\u20133.15,\n P<\/jats:italic>\n \u2009&lt;\u20090.001), with low heterogeneity (I\n 2<\/jats:sup>\n \u2009=\u200923.6%). An elevated risk was also noted for CV death (2 studies; OR\u2009=\u20092.79, 95% CI 1.28\u20136.08,\n P<\/jats:italic>\n \u2009=\u20090.010). For all-cause mortality (3 studies), the pooled OR was 2.33, but did not reach statistical significance (\n P<\/jats:italic>\n \u2009=\u20090.084). Between-subgroup heterogeneity tests indicated statistically significant differences in effects (all\n P<\/jats:italic>\n \u2009&lt;\u20090.01). Further analyses within the long-term follow-up subgroup revealed more pronounced protective effects among older patients (&gt; 65 years), mixed CAD cohorts, and those with a\u2009&gt;\u200970% male proportion. Studies not excluding liver disease showed more robust protective effects, though very few in number. Dose-response analysis showed that no linear or nonlinear association was observed (OR\u2009=\u20090.969, 95% CI 0.919\u20131.022,\n P<\/jats:italic>\n \u2009=\u20090.252). Sensitivity analysis based on the leave-one-out method revealed robust pooled results. Begg's test and Egger's test demonstrated that no significant publication bias was detected (all\n P<\/jats:italic>\n \u2009&gt;\u20090.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Serum total bilirubin shows a context-dependent bidirectional association with adverse outcomes in patients with CHD after PCI, but does not demonstrate a consistent independent prognostic value. The apparent protective effect observed in long-term follow-up, older, or stable CHD populations and the risk-elevating effect in the in-hospital acute phase are exploratory findings that require further validation. Given the extremely high heterogeneity (mainly due to inconsistencies in MACE endpoint definitions, liver disease exclusion criteria, and CHD subtype classifications) and the negative dose-response analysis (likely underpowered), current evidence does not support total bilirubin as a robust or generalizable prognostic biomarker. Future prospective studies with standardized designs are needed to elucidate its potential clinical utility.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1067176<\/jats:ext-link>\n , identifier CRD420251067176.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1783537","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:20Z","timestamp":1785385340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of total bilirubin level for patients suffering from coronary heart disease undergoing percutaneous coronary intervention: a meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhouxin","family":"Wu","sequence":"first","affiliation":[{"name":"First School of Clinical Medicine, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchuang","family":"Li","sequence":"additional","affiliation":[{"name":"First School of Clinical Medicine, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","first-page":"10729","article-title":"Efficacy and safety of coronary stent intervention for coronary heart disease and its impact on short-term and long-term prognosis","volume":"13","author":"Zhang","year":"2021","journal-title":"Am J Transl Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4291\/wjgp.v8.i2.51","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk","volume":"8","author":"Patil","year":"2017","journal-title":"World J Gastrointest Pathophysiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/clinchem\/40.1.18","article-title":"Association of low serum concentration of bilirubin with increased risk of coronary artery disease","volume":"40","author":"Schwertner","year":"1994","journal-title":"Clin Chem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e42594","DOI":"10.1371\/journal.pone.0042594","article-title":"Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12872-022-02607-8","article-title":"Serum total bilirubin and long-term prognosis of patients with new-onset non-ST elevation myocardial infarction: a cohort study","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jacc.2007.10.034","article-title":"The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention","volume":"51","author":"Kip","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/clinchem\/40.10.1987","article-title":"Is bilirubin protective against coronary artery disease?","volume":"40","author":"Breimer","year":"1994","journal-title":"Clin Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/clinchem\/46.11.1723","article-title":"Association of serum bilirubin concentration with risk of coronary artery disease","volume":"46","author":"Mayer","year":"2000","journal-title":"Clin Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2796.2012.02576.x","article-title":"Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis","volume":"273","author":"Stender","year":"2013","journal-title":"J Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.exger.2015.09.014","article-title":"Serum total bilirubin levels and coronary heart disease\u2013causal association or epiphenomenon?","volume":"72","author":"Kunutsor","year":"2015","journal-title":"Exp Gerontol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/ATVBAHA.114.304929","article-title":"Circulating total bilirubin and risk of incident cardiovascular disease in the general population","volume":"35","author":"Kunutsor","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12872-022-02899-w","article-title":"Role of bilirubin in the prognosis of coronary artery disease and its relationship with cardiovascular risk factors: a meta-analysis","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.numecd.2021.01.002","article-title":"Physiologically increased total bilirubin is associated with reduced risk of first myocardial infarction: a meta-analysis and dose-response analysis","volume":"31","author":"Yao","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.molmed.2023.01.007","article-title":"The physiology of bilirubin: health and disease equilibrium","volume":"29","author":"Vitek","year":"2023","journal-title":"Trends Mol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.3029864","article-title":"Bilirubin is an antioxidant of possible physiological importance","volume":"235","author":"Stocker","year":"1987","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2337\/db14-1391","article-title":"Unconjugated bilirubin mediates heme oxygenase-1-induced vascular benefits in diabetic mice","volume":"64","author":"Liu","year":"2015","journal-title":"Diabetes"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1096\/fj.04-2368fje","article-title":"Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats","volume":"19","author":"Lanone","year":"2005","journal-title":"Faseb j"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.01.001","article-title":"Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin","volume":"198","author":"Schwertner","year":"2008","journal-title":"Atherosclerosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","article-title":"Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the framingham heart study","volume":"114","author":"Lin","year":"2006","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/apha.12858","article-title":"Chronically elevated bilirubin protects from cardiac reperfusion injury in the male gunn rat","volume":"220","author":"Bakrania","year":"2017","journal-title":"Acta Physiol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12012-017-9405-3","article-title":"Association of fasting Serum bilirubin levels with clinical outcomes after percutaneous coronary intervention: a prospective study","volume":"17","author":"Zhang","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1050785","DOI":"10.3389\/fcvm.2022.1050785","article-title":"Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction","volume":"9","author":"Fang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/TCRM.S203433","article-title":"Higher serum total bilirubin predicts high risk of 3-year adverse outcomes in patients undergoing primary percutaneous coronary intervention","volume":"15","author":"Gao","year":"2019","journal-title":"Ther. Clin. Risk. Manag."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1253\/circj.CJ-15-1397","article-title":"Initial total bilirubin and clinical outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents","volume":"80","author":"Chung","year":"2016","journal-title":"Circ. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5114\/pwki.2014.43513","article-title":"A novel predictor of infarct-related artery patency before percutaneous intervention and in-hospital outcomes for ST-segment elevation myocardial infarction patients: serum bilirubin level","volume":"10","author":"Acet","year":"2014","journal-title":"Postepy Kardiol. Interwencyjnej"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e031227","DOI":"10.1136\/bmjopen-2019-031227","article-title":"Predicting value of white cell count and total bilirubin on clinical outcomes in patients with ST-elevation myocardial infarction following percutaneous coronary intervention: a cohort study","volume":"10","author":"Tuxun","year":"2020","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.clinsp.2023.100306","article-title":"Predictive values of bilirubin for in-hospital adverse events in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention","volume":"78","author":"Ying","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"B29","first-page":"15930","article-title":"Prognostic value of total bilirubin in patients with angina pectoris undergoing percutaneous coronary intervention","volume":"8","author":"Yao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.amjcard.2012.09.011","article-title":"Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention","volume":"111","author":"Gul","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"615254","DOI":"10.3389\/fcvm.2020.615254","article-title":"Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention","volume":"7","author":"Zhao","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00059-013-3828-9","article-title":"Serum biomarkers and the prognosis of AMI patients","volume":"39","author":"Wei","year":"2014","journal-title":"Herz"},{"key":"B33","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.25011\/cim.v37i5.22015","article-title":"Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention","volume":"37","author":"Zhang","year":"2014","journal-title":"Clin. Invest. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00380-014-0546-z","article-title":"Usefulness of serum bilirubin levels as a biomarker for long-term clinical outcomes after percutaneous coronary intervention","volume":"30","author":"Kim","year":"2015","journal-title":"Heart Vessels"},{"key":"B35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12872-026-05680-5","article-title":"Association of serum total bilirubin with recurrent cardiovascular events in patients with in-stent restenosis: a stratified analysis by inflammatory status","volume":"26","author":"Yu","year":"2026","journal-title":"BMC Cardiovasc. Disord."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1783537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:22:21Z","timestamp":1785385341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1783537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"alternative-id":["10.3389\/fcvm.2026.1783537"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1783537","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1783537"}}